Edgewise Therapeutics, Inc. EWTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Edgewise Therapeutics, Inc. (EWTX) reported comprehensive income (loss), net of tax, attributable to parent of -$49.94M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 22.4% year-over-year, from -$40.82M to -$49.94M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 40.2% compound annual growth rate (CAGR), from -$43.33M to -$167.54M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items like unrealized gains or losses on investments. It provides a comprehensive view of the company's total financial performance beyond the standard net income figure. This is a critical measure for assessing the overall impact of both operational results and market-driven valuation changes on shareholder equity.